Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera, ...

Novo Nordisk's surprise bid for Metsera has set the stage for a high-stakes showdown in the obesity drug market, with Pfizer ...

Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...